HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy
Author:
Affiliation:
1. Department of Dermatology; Tohoku University Graduate School of Medicine; Sendai Japan
2. Department of Dermatology; Kyoto University Graduate School of Medicine; Kyoto Japan
3. HLA Foundation Laboratory; Kyoto Japan
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.14273/fullpdf
Reference12 articles.
1. Ocular toxicity due to Trametinib and Dabrafenib;Sarny;BMC Ophthalmol,2017
2. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma;Matsuo;Clin Case Rep,2017
3. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient;Arai;J Dermatol,2017
4. Uveitis as a Result of MAP Kinase Pathway Inhibition;Joshi;Case Rep Ophthalmol,2013
5. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib;Draganova;J Ophthalmic Inflamm Infect,2015
Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Case Report and Literature Review of Vogt-Koyanagi-Harada-Like Uveitis Secondary to Dabrafenib and Trametinib: 4-Year Follow-Up Using Retinal Multimodal Imaging;Ocular Immunology and Inflammation;2024-09-09
2. Development of Vogt–Koyanagi–Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report;BMC Ophthalmology;2024-06-07
3. Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review;Diagnostics;2024-02-04
4. Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA‐DRB1*04;The Journal of Dermatology;2023-12-19
5. A case of melanoma complicated with uveitis induced by two types of BRAF/MEK inhibitors and nivolumab treatment;The Journal of Dermatology;2023-11-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3